Skip to main content
SpringerLink
Log in

Oligonucleotide-based drugs in the control of cytokine synthesis

  • Chapter
Book cover Novel Cytokine Inhibitors

Part of the book series: Progress in Inflammation Research ((PIR))

Abstract

As cytokines play key roles in physiological and pathophysiological processes, substantial research has been directed to identifying and elucidating the structures and functions of various cytokines and to understanding the processes that regulate them. Significant efforts have also been directed toward the identification of selective inhibitors of many of the cytokines (for review, see [1]).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Henderson B, Bodmer MW (eds) (1996)Therapeutic modulation of cytokines.CRC Press, Inc, Boca Raton, FL

    Google Scholar 

  2. Bennett CF, Crooke ST (1996) Oligonucleotide-based inhibitors of cytokine expression and function. In: B Henderson, M Bodmer (eds):Therapeutic modulation of cytokines.CRC Press, Inc, Boca Raton, FL, 171–193

    Google Scholar 

  3. Krieg AM (1998) Immune stimulation by oligonucleotides. In: ST Crooke (ed):Hand-book of experimental pharmacology: Antisense research and application.Springer-Verlag, Berlin, Heidelberg, 243–262

    Google Scholar 

  4. Neilsen PE (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide.Science254: 1497–1500

    Article  Google Scholar 

  5. Mollegaard NE, Buchardt O, Egholm M, Nielsen PE (1994) PNA-DNA strand displacement loops as artificial transcription promoters.Proc Natl Acad Sci USA91: 3892–3895

    Article  PubMed  CAS  Google Scholar 

  6. Sun JS, Helene C (1993) Oligonucleotide-directed triple-helix formation.Curr Opin Struct Biol3(3): 345–356

    CAS  Google Scholar 

  7. Bielinska A, Shivdasani RA, Zhang L, Nabel GJ (1990) Regulation of gene expression with double-stranded phosphorothioate oligonucleotides.Science250: 997–1000

    Article  PubMed  CAS  Google Scholar 

  8. Stein CA, Cheng Y-C (1993) Antisense oligonucleotides as therapeutic agents-Is the bul-let really magical?Science261: 1004–1012

    Article  PubMed  CAS  Google Scholar 

  9. Wagner RW (1994) Gene inhibition using antisense oligodeoxynucleotides.Nature372: 333–335

    Article  PubMed  CAS  Google Scholar 

  10. Crooke ST (1997) Advances in understanding the pharmacological properties of anti-sense oligonucleotides. In: B Weiss (ed):Antisense oligodeoxynucleotides and antisense RNA novel pharmacological and therapeutic agents.CRC Press, Boca Raton, 17–25

    Google Scholar 

  11. Wu H, Macleod AR, Lima WF, Crooke ST (1998) Identification and partial purification of human double strand RNase activity A novel terminating mechanism for oligoribonucleotide antisense drugs.J Biol Chem273 (5): 2532–2542

    Article  PubMed  CAS  Google Scholar 

  12. Crooke ST (1996) Advances in understanding the pharmacological properties of anti-sense oligonucleotides.Advances in Pharmacology40: 1–49

    Article  Google Scholar 

  13. Crouch RJ, Dirksen M-L (1985) Ribonucleases H. In: SM Linn, RJ Roberts (eds):Nucleases.Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 211–241

    Google Scholar 

  14. Wu H, Lima WF, Crooke ST (1998) Molecular cloning and expression of cDNA for human RNase H.Antisense Nucleic Acid Drug Dev8(1): 53–61

    Article  PubMed  CAS  Google Scholar 

  15. Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. JBiol Chem266: 18162–18171

    CAS  Google Scholar 

  16. Dean NM, McKay R (1994) Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.Proc Natl Acad Sci USA91: 11762–11766

    Article  PubMed  CAS  Google Scholar 

  17. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szczylik C, Iversen P, Iozzo RV, Zon G, Calabretta B (1994) Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.Proc Natl Acad Sci USA91: 4504–4508

    Article  PubMed  CAS  Google Scholar 

  18. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G, Gewirtz AM (1994) Biologic and therapeutic significance of MYB expression in human melanoma.Proc Natl Acad Sci USA91: 4499–4503

    Article  PubMed  CAS  Google Scholar 

  19. Greig MJ, Gaus H, Cummins LL, Sasmor H, Griffey RH (1995) Measurement of macro-molecular binding using electrospray mass spectrometry Determination of dissociation constants for oligonucleotide: Serum albumin complexes.J Am Chem Soc117 (43): 10765–10766

    Article  CAS  Google Scholar 

  20. Joos RW, Hall WH (1969) Determination of binding constants of serum albumin for penicillin.J Pharmacol Exp Ther166: 113

    PubMed  CAS  Google Scholar 

  21. Agrawal S, Temsamani J, Tang JY (1991) Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.Proc Natl Acad Sci USA88: 7595–7599

    Article  PubMed  CAS  Google Scholar 

  22. Srinivasan SK, Iversen P (1995) Review ofin vivopharmacokinetics and toxicology of phosphorothioate oligonucleotides.J Clin Lab Anal9: 129–137

    Article  PubMed  CAS  Google Scholar 

  23. Cossum PA, Truong L, Owens SR, Markham PM, Shea JP, Crooke ST (1994) Pharmacokinetics of a14C-labeled phosphorothioate oligonucleotide ISIS 2105, after intradermal administration to rats.J Pharm Exp Ther269: 89–94

    CAS  Google Scholar 

  24. Crooke ST, Grillone LR, Tendolkar A, Garrett A, Fratkin MJ, Leeds J, Barr WH (1994) A pharmacokinetic evaluation of 14C-labeled afovirsen sodium in patients with genital warts.Clin Pharm Therap56: 641–646

    Article  PubMed  CAS  Google Scholar 

  25. Cossum PA, Sasmor H, Dellinger D, Truong L, Cummins L, Owens SR, Markham PM, Shea JP, Crooke S (1993) Disposition of the14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.J PharmacolExpTher267: 1181–1190

    CAS  Google Scholar 

  26. Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL (1994) Biodistribution and metabolism of internally3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.Mol Pharmacol45: 932–943

    PubMed  CAS  Google Scholar 

  27. Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis-Farrar KM, Stecker KK, Martin MJ, Crooke RM (1998)In vivodistribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration.J Pharmacol Exp Ther286: 447–458

    PubMed  CAS  Google Scholar 

  28. Sands H, Gorey-Feret LJ, Ho SP, Bao Y, Cocuzza AJ, Chidester D, Hobbs FW (1995) Biodistribution and metabolism of internally3H-labeled oligonucleotides II 3’,5’-blocked oligonucleotides.Mol Pharmacol47: 636–646

    PubMed  CAS  Google Scholar 

  29. Crooke ST, Bennett CF (1996) Progress in antisense oligonucleotide therapeutics.Ann Rev Pharmacol Toxicol36: 107–129

    Article  CAS  Google Scholar 

  30. Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ (1997) Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice.Antisense Nucleic Acid Drug Dev7(5): 473–481

    Article  PubMed  CAS  Google Scholar 

  31. Levin AA, Monteith DK, Leeds JM, Nicklin PL, Geary RS, Butler M, Templin MV, Henry SP (1998) Toxicity of oligodeoxynucleotide therapeutic agents. In:Handbook of experimental pharmacology: Antisense research and application.Springer-Verlag, Berlin, Heidelberg.

    Google Scholar 

  32. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett F, Crooke ST (1997) Immune stimulation — a class effect of phosphorothioate oligodeoxynucleotides in rodents.Anti-cancer Drug Design12(5): 421–432

    PubMed  CAS  Google Scholar 

  33. Muccioli C, Goldstein DA, Johnson DW, Perez JE, Mora-Duarte JF, Sheppard JD, Man-sour SE, Chan CK, Palestine AG, Grillone LR et al (1998) Fomivirsen safety and efficacy in the treatment of CMV retinitis: A Phase 3, controlled, multicenter study comparing immediate versus delayed treatment. In:5th Conference on retroviruses and opportunistic infectionsSheraton Chicago Hotel, Chicago, IL

    Google Scholar 

  34. Gewirtz AM (1997) Developing oligonucleotide therapeutics for human leukemia.Anti-Cancer Drug Design12(5): 341–358

    PubMed  CAS  Google Scholar 

  35. Sikic GI, Yuen AR, Halsey J, Fisher GA, Pribble JP, Smith RM, Geary R, Dorr A (1997) A Phase I trial of an antisense oligonucleotide targeted to protein kinase C-α (ISIS 3521) delivered by twenty-one day continuous intravenous infusion. In:33rd Annual Meeting of the American Society of Clinical OncologyDenver, CO

    Google Scholar 

  36. O’Dwyer PJ, Stevenson JP, Gallagher M, Mitchell E, Friedland D, Rose L, Cassella A, Holmlund J, Dean N, Dorr A et al (1998) Phase I/phamracokinetic/pharmacodynamic trial of raf-1 antisense ODN (ISIS 5132, CGP 69846A). In:34th Annual Meeting of the American Society of Clinical OncologyLos Angeles, CA

    Google Scholar 

  37. Muccioli C, Goldstein DA, Perez JE, Mora-Duarte JF, Sheppard JD, Mansour SE, Chan CK, Palestine AG, Holland GN, Pelkey WL et al (1998) Safety and efficacy of fomivirsen in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment. In:8th international Congress on Infectious DiseasesBoston, MA

    Google Scholar 

  38. Glover JM, Leeds JM, Mant TGK, Amin D, Kisner D, Zuckerman J, Geary RS, Levin A, Shanahan JWR (1997) Phase 1 safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).J Pharmacol Exp Ther282: 1173–1180

    PubMed  CAS  Google Scholar 

  39. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Rothlein RA, Mainolfi E, Tami JA, Bennett CF, Kisner DL, Shanahan WR (1998) A placebo-controlled trial of ISIS 2302 (ICAM-1 antisense oligonucleotide) in the treatment of steroid-dependent Crohn’s disease.Gastroenterology114: 1133–1142

    Article  PubMed  CAS  Google Scholar 

  40. Shanahan WR (1998) Properties of ISIS 2302, an inhibitor of intercellular adhesion molecule-1, in humans. In: ST Crooke (ed):Handbook of experimental pharmacology: Antisense research and application.Springer-Verlag, Berlin, Heidelberg, 499–524

    Google Scholar 

  41. Milligan JF, Matteucci MD, Martin JC (1993) Current concepts in antisense drug design.J Med Chem36: 1923–1937

    Article  PubMed  CAS  Google Scholar 

  42. Sanghvi YS, Cook PD (1993) Towards second-generation synthetic backbones for anti-sense oligonucleosides. In: CK Chu, DC Baker (eds):Nucleosides nucleotides as antiviral and antitumor agents.Plenum Press, New York, 309–322

    Google Scholar 

  43. Beaucage SL, Iyer RP (1993) The synthesis of modified oligonucleotides by the phosphoramidite approach and their applications.Tetrahedron49: 6123–6194

    Article  CAS  Google Scholar 

  44. Sanghvi YS, Cook PD (1994) Carbohydrates: Synthetic methods and applications in antisense therapeutics: An overview. In: YS Sanghvi, PD Cook (eds):Carbohydrate modifications in antisense research. ACS Symposium Series No 580, American Chemical Society: Washington, DC 1–22

    Chapter  Google Scholar 

  45. Sagi J, Szemzo A, Ebinger K, Szabolocs A, Sagi G, Ruff E, Otvos L (1993) Base-modified oligodeoxynucleotides I Effect of 5-alkyl, 5-(1-alkenyl) and 5-(1-alkynyl) substitution of the pyrmidines on duplex stability and hydrophobicity.Tetrahedron Letters34: 2191–2194

    Article  CAS  Google Scholar 

  46. Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C, Froehler BC (1993) Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.Science260 (5113): 1510–1513

    Article  PubMed  CAS  Google Scholar 

  47. Iribarren AM, Sproat BS, Neuner P, Sulston I, Ryder U, Lamond AI (1990) 2’-O-alkyl oligoribonucleotides as antisense probes.Proc Natl Acad Sci USA87(19): 7747–7751

    Article  PubMed  CAS  Google Scholar 

  48. Kawasaki AM, Casper MD, Freier SM, Lesnik EA, Zounes MC, Cummins LL, Gonzalez C, Cook PD (1993) Uniformly modified 2’-deoxy-2’-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets.J Med Chem36: 831–841

    Article  PubMed  CAS  Google Scholar 

  49. Lesnik EA, Guinosso CJ, Kawasaki AM, Sasmor H, Zounes M, Cummins LL, Ecker DJ, Cook PD, Freier SM (1993) Oligodeoxynucleotides containing 2’-O-modified adenosine: Synthesis and effects on stability of DNA: RNA duplexes.Biochemistry32: 7832–7838

    Article  PubMed  CAS  Google Scholar 

  50. Martin P (1995) New access to 2’-O-alkylated ribonucleosides and properties of 2’-Oalkylated oligoribonucleotides.Helv Chim Acta78: 486–504

    Article  CAS  Google Scholar 

  51. Cummins LL, Owens SR, Risen LM, Lesnik EA, Freier SM, McGee D, Guinosso CJ, Cook PD (1995) Characterization of fully 2’-modified oligoribonucleotide hetero-and homoduplex hybridization and nuclease sensitivity.Nucleic Acids Res23 (11): 2019–2024

    Article  PubMed  CAS  Google Scholar 

  52. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM (1993) Evaluation of 2’ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression.J Biol Chem268: 14514–14522

    PubMed  CAS  Google Scholar 

  53. Agrawal S, Mayrand SH, Zamecnik PC, Pederson T (1990) Site-specific excision from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.Proc Natl Acad Sci USA87: 1401–1405

    Article  PubMed  CAS  Google Scholar 

  54. Lamond AI, Barabino S, Blencowe BJ, Sproat B, Ryder U (1990) Studying pre-mRNA splicing using antisense 2-OMe RNA oligonucleotides.Mol Biol Rep14: 201

    Article  PubMed  CAS  Google Scholar 

  55. Miller PS, McParland KB, Jayaraman K, Ts’o P (1981) Biochemical and biological effects of nonionic nucleic acid methylphosphonates.Biochemistry20: 1874–1880

    Article  PubMed  CAS  Google Scholar 

  56. Miller PS, Ts’o P (1987) A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression).Anti-Cancer Drug Design2: 117–128

    PubMed  CAS  Google Scholar 

  57. Miller PS (1991) Oligonucleoside methylphosphonates as antisense reagents.BioTechnology9: 358–362

    Article  PubMed  CAS  Google Scholar 

  58. Arnold LJ (1995) The development of oligonucleotides containing chirally pure methylphosphonates as therapeutic agents.Antisense Res Dey5: 108

    Google Scholar 

  59. Vasseur JJ, Debart F, Sanghvi YS, Cook PD (1992) Oligonucleosides: synthesis of a novel methylhydroxylamine-linked nucleoside dimer and its incorporation into anti-sense sequences.J Am Chem Soc114 (10): 4006–4007

    Article  CAS  Google Scholar 

  60. De Mesmaeker A, Lebreton J, Waldner A, Fritsch V, Wolf RM, Freier SM (1993) Amides as substitute for the phosphodiester linkage in antisense oligonucleotides.Synlett10: 733–736

    Article  Google Scholar 

  61. Jones RJ, Lin K-Y, Milligan JF, Wadwani S, Matteucci MD (1993) Synthesis and binding properties of pyrimidine oligodeoxynucleoside analogs containing neutral phosphodiester replacements The formacetal and 3’-thioformacetal internucleoside linkages.J Org Chem58: 2983–2991

    Article  CAS  Google Scholar 

  62. Crooke ST (1995)Therapeutic applications of oligonucleotides.RG Landes Company, Austin, 138

    Google Scholar 

  63. Buchardt O, Egholm M, Berg RH, Nielsen PE (1993) Peptide nucleic acids (PNA) and their potential applications in medicine and biotechnology.Trends BioTechnology11: 384–386

    Article  CAS  Google Scholar 

  64. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE (1993) PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules.Nature365: 566–568

    Article  PubMed  CAS  Google Scholar 

  65. Stirchak EP, Summerton JE, Weller DD (1989) Uncharged stereoregular nucleic acid analogs: 2 Morpholino nucleoside oligomers with carbamate internucleotide linkages.Nucleic Acids Research17: 6129–6141

    Article  PubMed  CAS  Google Scholar 

  66. Letsinger RL, Zhang GR, Sun DK, Ikeuchi T, Sarin PS (1989) Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture.Proc Natl Acad Sci USA86: 6553–6556

    Article  PubMed  CAS  Google Scholar 

  67. Torrence PF, Maitra RK, Lesiak K, Khamnei S, Zhou A, Silverman RH (1993) Targeting RNA for degradation with a (2’-5’)oligoadenylate-antisense chimera.Proc Natl Acad Sci USA90: 1300–1304

    Article  PubMed  CAS  Google Scholar 

  68. Manoharan M, Johnson LK, Bennett CF, Vickers TA, Ecker DJ, Cowsert LM, Freier SM, Cook PD (1994) Cholic acid-oligonucleotide conjugates for antisense applications.Bioorganic & Medicinal Chemistry Letters4: 1053–1060

    Article  CAS  Google Scholar 

  69. Manoharan M, Tivel KL, Andrade LK, Mohan V, Condon TP, Bennett CF, Cook PD (1995) Oligonucleotide conjugates: Alteration of the pharmacokinetic properties of anti-sense agents.Nucleosides Nucleotides14 (3–5): 969–973

    CAS  Google Scholar 

  70. Harel-Bellan A, Durum S, Muegge K, Abbas AK, Farrar WL (1988) Specific inhibition of lymphokine biosynthesis and autocrine growth using antisense oligonucleotides in TH1 and Th2 helper T cell clones.J Exp Med168: 2309–2318

    Article  PubMed  CAS  Google Scholar 

  71. Zubiaga AM, Munoz E, Huber BT (1991) Production of IL-1 alpha by activated Th type 2 cells Its role as an autocrine growth factor.J Immunol146: 3849–3856

    PubMed  CAS  Google Scholar 

  72. Miles SA, Rezai AR, Salazar-Gonz lez JF, Meyden MV, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T et al (1990) AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.Proc Natl Acad Sci USA87: 4068–4072

    Article  PubMed  CAS  Google Scholar 

  73. Levy Y, Tsapis A, Brouet J-C (1991) Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines.J Clin Invest88: 696–699

    Article  PubMed  CAS  Google Scholar 

  74. Schadendorf D, Moller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM (1993) IL-8 produced by human malignant melanoma cellsin vitrois an essential autocrine growth factor.J Immunol151: 2667–2675

    PubMed  CAS  Google Scholar 

  75. Birchenall-Roberts MC, Ferrer C, Ferris D, Falk LA, Kasper J, Gretchen W, Ruscetti FW (1990) Inhibition of murine monocyte proliferation by a colony-stimulating factor-1 antisense oligodeoxynucleotide Evidence for autocrine regulation.J Immunol145: 3290–3296

    PubMed  CAS  Google Scholar 

  76. Fujiwara T, Grimm EA (1992) Specific inhibition of interleukin 10 gene expression by an antisense oligonucleotide: Obligatory role of interleukin 1 in the generation of lymphokine-activated killer cells.Cancer Res52: 4954–4959

    PubMed  CAS  Google Scholar 

  77. Maier JAM, Voulalas P, Roeder D, Maciag T (1990) Extension of the life-span of human endothelial cells by an interleukin-1a antisense oligomer.Science249: 1570–1574

    Article  PubMed  CAS  Google Scholar 

  78. Garfinkel S, Haines DS, Brown S, Wessendorf J, Gillespie DH, Maciag T (1992) Inter-leukin-la mediates an alternative pathway for the antiproliferative action of poly(I-C) on human endothelial cells.J Biol Chem267: 24375–24378

    PubMed  CAS  Google Scholar 

  79. Benbernou N, Matsiota-Bernard P, Guenounou M (1993) Effect of cytokine-specific antisense oligonucleotides on the immunoglobulin production by rat spleen cellsin vitro. Biochimie75: 55–61

    Article  CAS  Google Scholar 

  80. Benbernou N, Matsiota-Bernard P, Guenounou M (1993) Antisense oligonucleotides to interleukin-4 regulate IgE and IgG2a production by spleen cells from Nippostrongylus brasiliensis-infected rats.Eur J Immunol23: 659–663

    Article  PubMed  CAS  Google Scholar 

  81. Burch RM, Mahan LC (1991) Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice.J Clin Invest88: 1190–1196

    Article  PubMed  CAS  Google Scholar 

  82. Bennett CF, Condon T, Grimm S, Chan H, Chiang M-Y (1994) Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides.J Immunol152: 3530–3540

    PubMed  CAS  Google Scholar 

  83. Segal GM, Smith TD, Heinrich MC, Ey FS, Bagby GC (1992) Specific repression of granulocyte-macrophage and granulocyte colony-stimulating factor gene expression in interleukin-1-stimulated endothelial cells with antisense oligodeoxynucleotides.Blood80: 609–616

    PubMed  CAS  Google Scholar 

  84. Thomae KR, Geller DA, Billiar TR, Davies P, Pitt BR, Simmons RL, Nakayama DK (1993) Antisense oligodeoxynucleotide to inducible nitric oxide synthase inhibits nitric oxide synthesis in rat pulmonary artery smooth muscle cells in culture.Surgery114: 272–277

    PubMed  CAS  Google Scholar 

  85. Maier JAM, Ragnotti G (1993) An oligomer targeted against protein kinase C prevents interleukin-1 induction of cyclooxygenase expression in human endothelial cells.Exp Cell Res205: 52–58

    Article  PubMed  CAS  Google Scholar 

  86. Dean NM, McKay R, Condon TP, Bennett CF (1994) Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.J Biol Chem269: 16416–16424

    PubMed  CAS  Google Scholar 

  87. Narayan R, Higgins KA, Perez JR, Coleman TA, Rosen CA (1993) Evidence for differential functions of the p50 and p65 subunits of NF-KB with a cell adhesion model.Mol Cell Biol13: 3802–3810

    Google Scholar 

  88. Sokoloski JA, Sartorelli AC, Rosen CA, Narayan R (1993) Antisense oligonucleotides to the p65 subunit of NF-kappaB block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes.Blood82: 625–632

    PubMed  CAS  Google Scholar 

  89. Griffin LC, Tidmarsh GF, Bock LC, Toole JJ, Leung LLK (1993)In vivoanticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits.Blood81: 3271–3276

    PubMed  CAS  Google Scholar 

  90. Nyce JW, Metzger WJ (1997) DNA antisense therapy for asthma in an animal model.Nature385 (6618): 721–725

    Article  PubMed  CAS  Google Scholar 

  91. Nyce JW (1997) Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases.Exp Opin Invest Drugs6 (9): 1149–1156

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA, 92008, USA

    Stanley T. Crooke

Authors
  1. Stanley T. Crooke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Celltech Chiroscience, 216 Bath Road, Slough Berkshire, SL1 4EN, UK

    Gerry A. Higgs

  2. Cellular Microbiology Research Group Eastman Dental Institute, University College London, 256 Gray’s Inn Road, London, WC1X 8LD, UK

    Brian Henderson

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this chapter

Cite this chapter

Crooke, S.T. (2000). Oligonucleotide-based drugs in the control of cytokine synthesis. In: Higgs, G.A., Henderson, B. (eds) Novel Cytokine Inhibitors. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8450-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8450-1_4

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9572-9

  • Online ISBN: 978-3-0348-8450-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation